Skip to main content
#ACR23 Abs 2463 data from first 3 pts suggest CD19 CAR-T provides possible drug-free remission and resolution of lung/mu

Dr. Rachel Tate

2 years 11 months ago
#ACR23 Abs 2463 data from first 3 pts suggest CD19 CAR-T provides possible drug-free remission and resolution of lung/muscle inflammation in antisynthetase syndrome. https://t.co/7udqkDBgqT @rheumnow https://t.co/LSHcI0HMTM
A#2547 #ACR23 @RheumNow
Diff 2 Treat (D2T) AxSpa
D2T: fail 2+ b/tsDMARDs w 2 MoA
Very D2T: failure of Rx in less than 2

Eric Dein

2 years 11 months ago
A#2547 #ACR23 @RheumNow Diff 2 Treat (D2T) AxSpa D2T: fail 2+ b/tsDMARDs w 2 MoA Very D2T: failure of Rx in less than 2 yrs 28% D2T, 3.8% Very D2T (Compare to 7-10% D2TRA) More likely: peripheral, uveitis, higher BASDAI, FM Very D2T also w IBD, higher CRP, longer dis duration https://t.co/HcIXnDRrIq
*not a cappuccino. The dregs of the coffee pot that the kind lady refused to charge me for.

But jet lag is kicking in h

David Liew drdavidliew

2 years 11 months ago
*not a cappuccino. The dregs of the coffee pot that the kind lady refused to charge me for. But jet lag is kicking in hard & so is desperation for any caffeine. If it wasn’t irAE friends @cappelliMD @jeffsparks et al up next, I would go to bed. #ACR23 must roll on! @RheumNow https://t.co/RdCOZlZMbZ
Another infusion option for axSpA!

INVIGORATE-1: Phase 3 RCT of IV Secukinumab in axSpA
Efficacious - ASAS40 response s

Robert B Chao, MD

2 years 11 months ago
Another infusion option for axSpA! INVIGORATE-1: Phase 3 RCT of IV Secukinumab in axSpA Efficacious - ASAS40 response sustained thru 52 weeks Safety profile similar to subq version @RheumNow #ACR23 Abs#2545 https://t.co/biC8p3p6dl
Pregnancies outcomes in vasculitis:
- Higher frequency of spontaneous abortion and preterm delivery
- 12% had pre-eclamp

Dr. Antoni Chan

2 years 11 months ago
Pregnancies outcomes in vasculitis: - Higher frequency of spontaneous abortion and preterm delivery - 12% had pre-eclampsia - Risk higher in multiparous > nalliparous - Risk highest in small vessel vasculitis Rector A, Abst#2425 #ACR23 #ACRBest @RheumNow https://t.co/TgbRWw9il5
Wouldn’t it be great to assess immune changes in #SLE before #clinical #lupus #flare? Without over treatment too! YOU

Janet Pope

2 years 11 months ago
Wouldn’t it be great to assess immune changes in #SLE before #clinical #lupus #flare? Without over treatment too! YOU CAN Lupus flare risk index calculated prior to disease activity change or stable pt. Results combined for score 11 mediators #ACR23 @RheumNow @ACRheum abst#2554 https://t.co/gUimJLrJ33
Body mass is associated w/ ttmt response in RA

Data from RACAT & TEAR studies

TNFi > triple th in underweight

Aurelie Najm

2 years 11 months ago
Body mass is associated w/ ttmt response in RA Data from RACAT & TEAR studies TNFi > triple th in underweight gpe but not in overweight gpe Similar result in gpe w/ low leptin levels & low adipokine scores True biology or confounding bias? @RheumNow #ACR23 ABST2541 https://t.co/OhKj6QNaSa
Baker et al. TNFi vs triple therapy by BMI. 907 patients from TEAR/RACAT. Those under/normal weight have a better respon

Richard Conway

2 years 11 months ago
Baker et al. TNFi vs triple therapy by BMI. 907 patients from TEAR/RACAT. Those under/normal weight have a better response to TNFi, overweight/obese respond equally to both. Abstr#2541 #ACR23 @RheumNow https://t.co/SROD3esMCD https://t.co/ni3I8tD7wI
Is rituximab still a problem with COVID - esp if our patients have been vaccinated pre-ritux?

Antibody titres better wh

David Liew drdavidliew

2 years 11 months ago
Is rituximab still a problem with COVID - esp if our patients have been vaccinated pre-ritux? Antibody titres better when not getting regular ritux around boosters Maybe boosters 9mo (or so) gap after ritux helps immunogenicity @TroldborgAnne et al #ACR23 ABST2511 @RheumNow https://t.co/dE0uC6B9hx
Acute anterior uveitis is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA) affecting up to 50% of patients in some age groups. AAU can have a significant impact on quality of life with risk of permanent visual deficits if not adequately treated. 
In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.
The American College of Rheumatology guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence.
The Lupus APOL1 Story

Dr. Kathryn Dao talks with Dr. Ashira Blazer, Rheumatology Research Foundation Dubois Memorial

Dr. John Cush RheumNow

2 years 11 months ago
The Lupus APOL1 Story Dr. Kathryn Dao talks with Dr. Ashira Blazer, Rheumatology Research Foundation Dubois Memorial Lecturer on APOL1 High Risk Genotype in SLE: A Genes in Context Story, at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23 https://t.co/VXxJxk0kbS https://t.co/1n1COXcYA4
ROMO vs DEN.
Romosozumab was superior to denosumab

(ROMO +7.3±4.5%; p< 0.001) and (DEN +2.3±3.1%; p< 0.001) i

Dr. Antoni Chan

2 years 11 months ago
ROMO vs DEN. Romosozumab was superior to denosumab (ROMO +7.3±4.5%; p< 0.001) and (DEN +2.3±3.1%; p< 0.001) in raising the spine BMD but not in hip at month 12 in chronic GC users with high fracture risk Mok C Abst#242 #ACR23 @RheumNow https://t.co/q2OKD6C2Me
×